Trial · NCT00320190
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Dasatinib, 100 mg | Deaths | 0 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Imatinib, 800 mg | Deaths | 0 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Dasatinib, 100 mg | AEs | 94.7 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Imatinib, 800 mg | AEs | 92.3 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Dasatinib, 100 mg | Treatment-related AEs | 78.9 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Imatinib, 800 mg | Treatment-related AEs | 92.3 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Dasatinib, 100 mg | SAEs | 15.8 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Imatinib, 800 mg | SAEs | 7.7 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Dasatinib, 100 mg | Treatment-related SAEs | 5.3 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Imatinib, 800 mg | Treatment-related SAEs | 7.7 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Dasatinib, 100 mg | AEs leading to discontinuation | 5.3 | Percentage of participants | |
| Percentage of Participants With Death as Outcome, Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, and AEs Leading to Discontinuation | Imatinib, 800 mg | AEs leading to discontinuation | 7.7 | Percentage of participants | |
| Percentage of Participants With On-study AEs of Special Interest | Dasatinib, 100 mg | Fluid retention (Any grade) | 5.3 | Percentage of Participants | |
| Percentage of Participants With On-study AEs of Special Interest | Imatinib, 800 mg | Fluid retention (Any grade) | 38.5 | Percentage of Participants | |
| Percentage of Participants With On-study AEs of Special Interest | Dasatinib, 100 mg | Fluid retention (Grades 3-5) | 0 | Percentage of Participants | |
| Percentage of Participants With On-study AEs of Special Interest | Imatinib, 800 mg | Fluid retention (Grades 3-5) | 7.7 | Percentage of Participants | |
| Percentage of Participants With On-study AEs of Special Interest | Dasatinib, 100 mg | Fluid retention: Superficial edema (Any grade) | 0 | Percentage of Participants | |
| Percentage of Participants With On-study AEs of Special Interest | Imatinib, 800 mg | Fluid retention: Superficial edema (Any grade) | 30.8 | Percentage of Participants | |
| Percentage of Participants With On-study AEs of Special Interest | Dasatinib, 100 mg | Fluid retention: Superficial edema (Grades 3-5) | 0 | Percentage of Participants | |
| Percentage of Participants With On-study AEs of Special Interest | Imatinib, 800 mg | Fluid retention: Superficial edema (Grades 3-5) | 0 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00320190/results